Bank of America
APLS

Bank of America’s Apellis Pharmaceuticals APLS Stock Holding History

Bank of America’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-84,100
Closed -$5.03M – 7712
2023
Q4 		$5.03M Buy
84,100
+31,400
+60% +$1.59M ﹤0.01% 3551
2023
Q3 		$2M Buy
+52,700
New +$2.31M ﹤0.01% 4238
2021
Q4 		– Sell
-149,200
Closed -$4.92M – 8188
2021
Q3 		$4.92M Buy
+149,200
New +$8.38M ﹤0.01% 3583

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America's APLS Position: Q1 2026 in Review

Bank of America increased its Apellis Pharmaceuticals (APLS) stake by 24% in Q1 2026, buying an estimated $5.04M and bringing the position to 1,190,864 shares worth $47.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Bank of America first reported a position in APLS in Q4 2017 and has held it in 34 quarters since. The position peaked at $68.5M in Q1 2025. 322 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Bank of America held 1,190,864 shares of Apellis Pharmaceuticals worth $47.9M as of Q1 2026.
  • Bank of America bought 234,091 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.04M.
  • Apellis Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1628 holding.
  • Bank of America first reported a position in Apellis Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
  • Bank of America's Apellis Pharmaceuticals position peaked at $68.5M in Q1 2025.
  • 322 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.